Thomas C. Krivak, MD

Articles

Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

December 27th 2023

Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.

Staging and Biomarker Testing For Patients With Cervical Cancer

December 27th 2023

David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.

Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

December 20th 2023

Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.

Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

December 20th 2023

The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.

Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

December 13th 2023

Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

December 13th 2023

The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.

The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

December 6th 2023

Dr Thomas C. Krivak highlights key data from the GY018 trial investigating chemotherapy plus pembrolizumab in both dMMR and pMMR advanced endometrial cancer, confirming and extending the findings from the RUBY trial supporting pembrolizumab's approval and use in both dMMR and pMMR populations.

Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

December 6th 2023

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

The Role of dMMR in the Progression of Endometrial Cancer

November 29th 2023

David M. O’Malley, MD, details the definition of dMMR (mismatch repair deficiency), its prevalence in advanced endometrial cancer, and current treatment approaches for dMMR patients, with a focus on the potential for cure in recurrent/metastatic dMMR patients based on clinical trial data.

Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

November 29th 2023

The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.

Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

November 22nd 2023

Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.

Diagnosing and Staging Patients With Endometrial Cancer

November 22nd 2023

Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.

HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations

August 2nd 2023

Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.

Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

August 2nd 2023

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

Commercially Available  HRD Tests for Ovarian Cancer

July 27th 2023

The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.

Other Causes of HRD: Chromosomal LOH, LST, and TAI

July 27th 2023

Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.

Defining HRD and its Role in Ovarian Cancer

July 20th 2023

Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).

Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann